Curtis W. Hayes, M.D., FACR

Professor

Curtis W. Hayes, M.D., FACR

Department: Radiology

Phone: (804) 828-0552

Fax: (804) 628-1132

Email: curtis.hayes@vcuhealth.org

Address/Location:
Main Hospital, Room 3-444

SPECIALTIES

  • Musculoskeletal Radiology
  • Musculoskeletal MRI
  • Musculoskeletal Intervention

AREAS OF INTEREST

  • Musculoskeletal radiology
  • Osteoporosis
  • Osteoarthritis
  • Musculoskeletal imaging-guided interventional procedures
  • Musculoskeletal tumors
  • Sports injuries and musculoskeletal trauma
  • Bone marrow abnormalities
  • Musculoskeletal MRI
  • Novel research methods of musculoskeletal imaging

RESEARCH PROJECTS/GRANTS

Title: A randomized, double-blinded, placebo-controlled, parallel group, multicenter study to compare the effect of one-year treatment with three dose levels of SB 462795 and placebo on cartilage structure in patients with knee osteoarthritis
Sponsor: GlaxoSmithKline, Inc.
Role: Analysis of subject knee osteoarthritis radiographic and MRI data

Title: A prospective, randomized, multidisciplinary, multicenter controlled study comparing minimally invasive reduction and fixation using KyphX System and KyphX radiopaque cement to medical therapy for the treatment of painful, acute vertebral body compression fractures
Sponsor: Kyphon, Inc.
Role: Analysis of subject radiographic spine and peripheral skeleton fracture data

Title: Comparison of the effects of teriparatide with those of alendronate sodium on lumbar spine bone mineral density in glucocorticoid-induced osteoporosis
Sponsor: Lilly, Inc.
Role: Analysis of subject radiographic spine and peripheral skeleton fracture data

Title: A multinational, multicenter, randomized, double-blind, double-dummy, stratified, active controlled parallel group study comparing the efficacy and safety of intravenous zoledronic acid, 5 mg once yearly, and oral risedronate, 5 mg daily, in the prevention and treatment of corticosteroid induced osteoporosis
Sponsor: Novartis, Inc.
Role: Analysis of subject radiographic spine and peripheral skeleton fracture data

Title: Randomized, multicenter, double-blind, double-dummy, parallel group study to determine the efficacy and safety of intravenous zoledronic acid, 5 mg annually, compared to oral alendronate, 70 mg weekly, for the treatment of osteoporosis in men
Sponsor: Novartis, Inc.
Role: Analysis of subject radiographic spine and peripheral skeleton fracture data

Title: Efficacy and safety of zoledronic acid in children (1-17 years) with severe osteogenesis imperfecta
Sponsor: Novartis, Inc.
Role: Analysis of subject radiographic spine and peripheral skeleton fracture data

Title: A long-term, randomized, double-blind, parallel-group, placebo-controlled, radiographic study to investigate the safety and efficacy of orally administered SD-6010 in subjects with symptomatic osteoarthritis of the knee
Sponsor: Pfizer, Inc.
Role: Analysis of images

Title: The effect of teriparatide compared with risedronate on back pain in postmenopausal women with osteoporotic vertebral fractures
Sponsor: Lilly, Inc.
Role: Analysis of images

Title: A phase IIIB open-label, randomized, multicenter study to evaluate the use of zoledronic acid in the prevention of cancer treatment-related bone loss in postmenopausal women with ER+ and/or PgR+ breast cancer receiving letrozole as adjuvant therapy
Sponsor: Novartis, Inc.
Role: Analysis of images

Title: An open-label, randomized, multicenter study to evaluate the skeletal and lipid profile effects of letrozole and tamoxifen in postmenopausal women with resected, receptor positive early breast cancer
Sponsor: Novartis, Inc.
Role: Analysis of images

Title: An osteoporosis study for spine fracture assessment and hip and spine density
Sponsor: Novartis, Inc.
Role: Analysis of images

Title: A one-year partial double-blinded, randomized, multicenter, multinational study to assess the effects of combination therapy of annual zoledronic acid (5 mg) and daily subcutaneous teriparatide (20 μg) on postmenopausal women with resected, receptor positive early breast cancer
Sponsor: Novartis, Inc.
Role: Analysis of images

Title: An open-label, randomized, multicenter study to evaluate the use of zoledronic acid in the prevention of cancer treatment-related bone loss in postmenopausal women with ER+ and/or PR+ breast cancer receiving letrozole as adjuvant therapy
Sponsor: Novartis, Inc.
Role: Analysis of images

Title: Computerized tool for assessing vertebral body shape
Sponsor: Novartis, Inc. and Optasia, Inc.
Role: Consultation on methodology and analysis of images

EDUCATION

  • M.D. – University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ
  • Residency, Diagnostic Radiology – Beth Israel Hospital, Boston, MA
  • Fellowship, Musculoskeletal Radiology – Massachusetts General Hospital, Harvard Medical School, Boston, MA

BOARD CERTIFICATION

  • American Board of Radiology

Back to Listing